A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants

Lilly

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: [14C]-LY3556050

Study type: Interventional

Funder types: Industry

Identifiers

NCT06052462

J2P-MC-LXBC (Other Identifier)

18347

Details and patient eligibility

About

The main purpose of this study is to evaluate how much of the study drug (LY3556050), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of the study drug gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 58 days including the screening period.

Enrollment: 7 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male participants who are overtly healthy as determined by medical evaluation
• Have a body mass index of 18.0 to 32.0 kilograms per meter squared (kg/m²), inclusive
• Males who agree to use highly effective or effective methods of contraception

Exclusion criteria

• Have known allergies to LY3556050, related compounds, or any components of the formulation of LY3556050, or history of significant atopy
• Have clinically significant abnormal BP and/or pulse rate as determined by the investigator
• Have had exposure to significant diagnostic, therapeutic, or employment-related radiation within 12 months prior to dosing

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

7 participants in 1 patient group

[14C]-LY3556050

Experimental group

Description:

Single dose of \[¹⁴C\]-LY3556050 administered orally

Treatment:

Drug: [14C]-LY3556050